MX2020004220A - Anticuerpos anti-glico-muc1 y sus usos. - Google Patents
Anticuerpos anti-glico-muc1 y sus usos.Info
- Publication number
- MX2020004220A MX2020004220A MX2020004220A MX2020004220A MX2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A
- Authority
- MX
- Mexico
- Prior art keywords
- glyco
- antibodies
- muc1
- antigen
- present disclosure
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación se refiere a anticuerpos anti-glico-MUC1 y fragmentos de unión a antigeno de los mismos que se unen especificamente a una variante de glicosilacion de MUC1 especifica de cáncer, y proteinas de fusión y conjugados anticuerpo-fármaco relacionados, asi como tambien ácidos nucleicos que codifican tales biomoleculas; la presente divulgación se refiere ademas al uso de los anticuerpos, fragmentos de unión a antigeno, proteinas de fusión, conjugados anticuerpofarmaco y ácidos nucleicos para la terapia del cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/058036 WO2019083506A1 (en) | 2017-10-24 | 2017-10-24 | ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004220A true MX2020004220A (es) | 2020-10-05 |
Family
ID=66247577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004220A MX2020004220A (es) | 2017-10-24 | 2017-10-24 | Anticuerpos anti-glico-muc1 y sus usos. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3700936A4 (es) |
| JP (2) | JP7358367B2 (es) |
| KR (2) | KR102608763B1 (es) |
| AU (1) | AU2017436815A1 (es) |
| BR (1) | BR112020008001A2 (es) |
| CA (1) | CA3078812A1 (es) |
| IL (1) | IL274202A (es) |
| MX (1) | MX2020004220A (es) |
| WO (1) | WO2019083506A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| EP2014302A1 (en) * | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
| KR20100097674A (ko) * | 2007-12-05 | 2010-09-03 | 교와 핫꼬 기린 가부시키가이샤 | 헤파린 결합 상피 세포 증식 인자 유사 증식 인자에 결합하는 단일 클론 항체 |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
-
2017
- 2017-10-24 BR BR112020008001-2A patent/BR112020008001A2/pt unknown
- 2017-10-24 KR KR1020207014390A patent/KR102608763B1/ko active IP Right Grant
- 2017-10-24 MX MX2020004220A patent/MX2020004220A/es unknown
- 2017-10-24 WO PCT/US2017/058036 patent/WO2019083506A1/en unknown
- 2017-10-24 AU AU2017436815A patent/AU2017436815A1/en active Pending
- 2017-10-24 KR KR1020237040745A patent/KR20230165874A/ko active Application Filing
- 2017-10-24 JP JP2020543460A patent/JP7358367B2/ja active Active
- 2017-10-24 EP EP17929557.1A patent/EP3700936A4/en active Pending
- 2017-10-24 CA CA3078812A patent/CA3078812A1/en active Pending
-
2020
- 2020-04-23 IL IL274202A patent/IL274202A/en unknown
-
2023
- 2023-09-27 JP JP2023165289A patent/JP2024001073A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7358367B2 (ja) | 2023-10-10 |
| EP3700936A4 (en) | 2021-05-26 |
| KR20200067885A (ko) | 2020-06-12 |
| KR20230165874A (ko) | 2023-12-05 |
| EP3700936A1 (en) | 2020-09-02 |
| KR102608763B1 (ko) | 2023-11-30 |
| JP2021510307A (ja) | 2021-04-22 |
| JP2024001073A (ja) | 2024-01-09 |
| AU2017436815A1 (en) | 2020-04-23 |
| CA3078812A1 (en) | 2019-05-02 |
| BR112020008001A2 (pt) | 2020-10-20 |
| WO2019083506A1 (en) | 2019-05-02 |
| IL274202A (en) | 2020-06-30 |
| CN111479828A (zh) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018070183A2 (pt) | neoantígenos e métodos de seu uso | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
| CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| CL2018000458A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| CO2017010502A2 (es) | Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b | |
| PE20171764A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 | |
| CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
| AR107078A1 (es) | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso | |
| PE20181013A1 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
| CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
| GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
| BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| MX2022010487A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| BR112018010102A2 (pt) | conjugados farmacêuticos de anticorpos sítio-específicos para her2 | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| PE20160528A1 (es) | Anticuerpos | |
| UY36678A (es) | Anticuerpos anti-fcrn. |